Is severe visceral leishmaniasis a systemic inflammatory response syndrome? - A case control study;A leishmaniose visceral grave é uma síndrome da resposta inflamatória sistêmica? - Um estudo caso-controle

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 4, 2010, Pages 386-392

  Costa, Carlos Henrique Nery ^a,b   Werneck, Guilherme Loureiro ^c,d   Costa, Dorcas Lamounier ^b,e   Holanda, Thiago Ayres ^b   Aguiar, Guilherme Brasileiro ^b   Carvalho, Aline Santos ^b   Cavalcanti, Janaína Costa ^b   Santos, Loryenne Santos ^b  

^a Laboratory of Leishmaniasis   (Brazil)

^b FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

AIDS; Bleeding; Kala azar; Severe inflammatory response syndrome; Visceral leishmaniasis

Indexed keywords

BILIRUBIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; DIARRHEA; DISEASE SEVERITY; DYSPNEA; EDEMA; FEMALE; HUMAN; INFANT; INFECTION RISK; JAUNDICE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PROTEINURIA; RISK ASSESSMENT; SCHOOL CHILD; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; VISCERAL LEISHMANIASIS; VOMITING;

BACTERIA (MICROORGANISMS); NASO HEXACANTHUS;

EID: 77957979610     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000400010     Document Type: Article

References (37)

1. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-1199.
2. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124:664-672.
3. Série histórica de óbitos e casos de doenças de notificação compulsória no Brasil (1980-2005): Departamento de Vigilância Epidemiológica. Coordenação Geral de Vigilância Epidemiológica. Secretaria de Vigilância em Saúde. Brasília; Ministério da Saúde; 2006.
4. Leishmaniose Visceral Grave: Normas e Condutas. Departamento de Vigilância Epidemiológica. Coordenação Geral de Vigilância Epidemiológica; Secretaria de Vigilância em Saúde. Brasília. Ministério da Saúde; 2006.
5. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174-177.
6. Abdelmoula MS, M'hamdi Z, Amri F, Tebib N, Ben Turkia H, Ben Dridi MF. La leishmaniose viscerale chez l'enfant: facteurs pronostiques. Tunis Med 2003; 81:535-539.
7. Collin S DR, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612-619.
8. Andrade TM, Carvalho EM Rocha H. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 1990; 162:1354-1359.
9. Queiroz MJ, Alves JG, Correia JB. Visceral leishmaniasis: clinical and epidemiological features of children in an endemic area. J Pediatr 2004; 80:141-146.
10. Lomtadze ML, Khochava MA, Shalamberidze IA, Kharaishvili VI, Vorob'eva EO. [Study of intravascular coagulation activation markers in patients with visceral leishmaniasis]. Georgian Med News; 2005. p. 47-50.
11. Baranwal AK, Mandal RN, Singh R. Fulminant hepatic failure complicating visceral leishmaniasis in an apparently immunocompetent child. IndianJ Pediatr 2007; 74:489-491.
12. Hietbrink F, Koenderman L, Rijkers G, Leenen L. Trauma: the role of the innate immune system. World J Emerg Surg 2006; 1:15.
13. Marwaha N, Sarode R, Gupta RK, Garewal G, Dash S. Clinico-hematological characteristics in patients with kala azar. A study from north-west India Trop Geogr Med 1991; 43:357-362.
14. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004; 114:321-327.
15. Al-Jurayyan NA, Al-Nasser MN, Al-Fawaz IM, Al Ayed IH, Al Herbish AS, Al-Mazrou AM, et al. The haematological manifestations of visceral leishmaniasis in infancy and childhood. J Trop Pediatr 1995; 41:143-148.
16. Dutra M, Martinelli R, Carvalho EM, Rodrigues LE, Brito E, Rocha H. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22-27.
17. Duarte MI, Matta VL, Corbett CE, Laurenti MD, Chebabo R, Goto H. Interstitial pneumonitis in human visceral leishmaniasis. Trans Rev Soc Trop Med Hyg 1989; 83:73-76.
18. El Hag IA, Hashim FA, El Toum IA, Homeida M, El Kalifa M, El Hassan AM. Liver morphology and function in visceral leishmaniasis (Kala-azar). J Clin Pathol 1994; 47:547-551.
19. Duarte MI, Corbett CE. Histopathological patterns of the liver involvement in visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 1987; 29:131-136.
20. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-1444.
21. Garg R, Trudel N, Tremblay MJ. Consequences of the natural propensity of Leishmania and HIV-1 to target dendritic cells. Trends Parasitol 2007; 23:317-324.
22. Duarte MI, Silva MR, Goto H, Nicodemo EL, Amato V. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 1983; 77:531-537.
23. Alonso MJ, Munoz E, Picazo A, Abad MM, Gomez F, Roldan M, et al. Duodenal leishmaniasis diagnosed by biopsy in two HIV-positive patients. Pathol Res Pract 1997; 193:43-47.
24. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93:319-323.
25. Wasunna KM, Raynes JG, Were JB, Muigai R, Sherwood J, Gachihi G, et al. Acute phase protein concentrations predict parasite clearance rate during therapy for visceral leishmaniasis. Trans R Soc Trop Med Hyg 1995; 89:678-681.
26. Alonso DP, Ferreira AF, Ribolla PE, Santos IK, Cruz M, Carvalho F, et al. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. J Infect Dis 2007; 195:1212-1217.
27. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva LA, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha+ monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 2006; 146:124-132.
28. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119:339-345.
29. Lagler H, Willheim M, Traunmuller F, Wahl K, Winkler H, Ramharter M, et al. Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10. Scand J Immunol 2003; 57:291-295.
30. Van Der Poll T, Zijlstra EE, Mevissen M. Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol 1995; 77:111-114.
31. Caldas A, Favali C, Aquino D, Vinhas V, Van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 2005; 5:113.
32. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204:805-817.
33. Weigand MA, Horner C, Bardenheuer HJ, Bouchon A. The systemic inflammatory response syndrome. Best Pract Res Clin Anaesthesiol 2004; 18:455-475.
34. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007; 18:335-343.
35. Schroder K, Hertzog PJ, RavasiT, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-189.
36. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8(supl 2): S3.
37. Remick DG. Interleukin-8. Crit Care Med 2005; 33:S466-467.